Honduras vs Namibia: Average cost of multi drug-resistant tuberculosis treatment
Honduras
3,743 constant 2022 US$
in 2024
Namibia
3,336 constant 2022 US$
in 2024
Honduras rank
11th
Namibia rank
14th
Average cost of multi drug-resistant tuberculosis treatment over time
- Honduras
- Namibia
How they compare
Honduras currently reports 3,743 constant 2022 US$ against 3,336 constant 2022 US$ in Namibia, a difference of 407 constant 2022 US$.
That makes Honduras's figure about 1.1 times Namibia's.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Namibia ahead.
Honduras ranks 11th and Namibia ranks 14th of 92 countries.
Namibia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Honduras | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,642 constant 2022 US$ | 5,099 constant 2022 US$ | 3,458 constant 2022 US$ | Namibia |
| 2020s | 1,891 constant 2022 US$ | 2,966 constant 2022 US$ | 1,075 constant 2022 US$ | Namibia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Honduras or Namibia?
- Honduras, at 3,743 constant 2022 US$ against 3,336 constant 2022 US$ in Namibia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Honduras and Namibia?
- 407 constant 2022 US$, with Honduras ahead.
- How many years of comparable data are there for Honduras and Namibia?
- 7 years are reported by both, from 2017 to 2024.
- How do Honduras and Namibia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Honduras ranks 11th and Namibia ranks 14th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.